HemoSphere Advanced Monitor, HemoSphere ClearSight Module— 510(k) K221833

Substantially Equivalent

Edwards Lifesciences, LLC

FDA 510(k) clearance K221833 for HemoSphere Advanced Monitor, HemoSphere ClearSight Module, Substantially Equivalent on 2022-11-07. Applicant: Edwards Lifesciences, LLC.

Clearance details

Applicant: Edwards Lifesciences, LLC
Product code: Code DXN
Advisory panel: Cardiovascular
Date received: 2022-06-23
Decision date: 2022-11-07
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Irvine, CA, US

Download summary PDF View on FDA.gov ↗

Adverse events under product code DXN

product code DXN

Death: 3
Injury: 169
Malfunction: 1,019
Other: 2
Total: 1,193

Source: openFDA MAUDE database, 2020-01-01 through 2026-04-23. Counts aggregate all devices under this product code, not just this specific clearance. Reports are submissions to FDA, not validated events. Search MAUDE directly →

Data sourced from openFDA. This site is unofficial and independent of the FDA.